Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

10x Genomics, Inc. (TXG)

Compare
9.16
-0.25
(-2.66%)
At close: March 28 at 4:00:01 PM EDT
9.00
-0.16
(-1.75%)
After hours: March 28 at 7:20:40 PM EDT
Loading Chart for TXG
  • Previous Close 9.41
  • Open 9.35
  • Bid 9.12 x 1300
  • Ask 9.20 x 2500
  • Day's Range 8.92 - 9.47
  • 52 Week Range 8.92 - 37.86
  • Volume 2,665,899
  • Avg. Volume 2,847,061
  • Market Cap (intraday) 1.12B
  • Beta (5Y Monthly) 1.93
  • PE Ratio (TTM) --
  • EPS (TTM) -1.52
  • Earnings Date Apr 28, 2025 - May 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.31

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

www.10xgenomics.com

1,306

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TXG

View More

Performance Overview: TXG

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TXG
36.21%
S&P 500 (^GSPC)
5.11%

1-Year Return

TXG
75.59%
S&P 500 (^GSPC)
6.22%

3-Year Return

TXG
86.99%
S&P 500 (^GSPC)
21.97%

5-Year Return

TXG
84.73%
S&P 500 (^GSPC)
119.59%

Compare To: TXG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TXG

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    1.12B

  • Enterprise Value

    809.50M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.81

  • Price/Book (mrq)

    1.58

  • Enterprise Value/Revenue

    1.33

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -29.90%

  • Return on Assets (ttm)

    -12.77%

  • Return on Equity (ttm)

    -25.17%

  • Revenue (ttm)

    610.79M

  • Net Income Avi to Common (ttm)

    -182.63M

  • Diluted EPS (ttm)

    -1.52

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    393.4M

  • Total Debt/Equity (mrq)

    11.63%

  • Levered Free Cash Flow (ttm)

    59.82M

Research Analysis: TXG

View More

Company Insights: TXG

Research Reports: TXG

View More

People Also Watch